IBDEI3CR ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,56335,0)
 ;;=51798^^258^2803^10^^^^1
 ;;^UTILITY(U,$J,358.3,56335,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56335,1,2,0)
 ;;=2^51798
 ;;^UTILITY(U,$J,358.3,56335,1,3,0)
 ;;=3^US For Residual Urine
 ;;^UTILITY(U,$J,358.3,56336,0)
 ;;=51727^^258^2803^1^^^^1
 ;;^UTILITY(U,$J,358.3,56336,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56336,1,2,0)
 ;;=2^51727
 ;;^UTILITY(U,$J,358.3,56336,1,3,0)
 ;;=3^CMG,Comp w/ UP Study
 ;;^UTILITY(U,$J,358.3,56337,0)
 ;;=51728^^258^2803^2^^^^1
 ;;^UTILITY(U,$J,358.3,56337,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56337,1,2,0)
 ;;=2^51728
 ;;^UTILITY(U,$J,358.3,56337,1,3,0)
 ;;=3^CMG,Comp w/ VP
 ;;^UTILITY(U,$J,358.3,56338,0)
 ;;=51729^^258^2803^3^^^^1
 ;;^UTILITY(U,$J,358.3,56338,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56338,1,2,0)
 ;;=2^51729
 ;;^UTILITY(U,$J,358.3,56338,1,3,0)
 ;;=3^CMG,Comp w/ VP & UP
 ;;^UTILITY(U,$J,358.3,56339,0)
 ;;=51736^^258^2803^12^^^^1
 ;;^UTILITY(U,$J,358.3,56339,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56339,1,2,0)
 ;;=2^51736
 ;;^UTILITY(U,$J,358.3,56339,1,3,0)
 ;;=3^Uroflow,Simple
 ;;^UTILITY(U,$J,358.3,56340,0)
 ;;=51784^^258^2803^7^^^^1
 ;;^UTILITY(U,$J,358.3,56340,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56340,1,2,0)
 ;;=2^51784
 ;;^UTILITY(U,$J,358.3,56340,1,3,0)
 ;;=3^EMG Non-Needle
 ;;^UTILITY(U,$J,358.3,56341,0)
 ;;=J9202^^258^2804^33^^^^3
 ;;^UTILITY(U,$J,358.3,56341,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56341,1,2,0)
 ;;=2^J9202
 ;;^UTILITY(U,$J,358.3,56341,1,3,0)
 ;;=3^Zoladex, 10.8 mg total
 ;;^UTILITY(U,$J,358.3,56342,0)
 ;;=96401^^258^2804^10^^^^1
 ;;^UTILITY(U,$J,358.3,56342,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56342,1,2,0)
 ;;=2^96401
 ;;^UTILITY(U,$J,358.3,56342,1,3,0)
 ;;=3^Chemotherapy,IM/SQ
 ;;^UTILITY(U,$J,358.3,56343,0)
 ;;=96402^^258^2804^19^^^^1
 ;;^UTILITY(U,$J,358.3,56343,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56343,1,2,0)
 ;;=2^96402
 ;;^UTILITY(U,$J,358.3,56343,1,3,0)
 ;;=3^Injec,IM,anti-neplastic horm
 ;;^UTILITY(U,$J,358.3,56344,0)
 ;;=96372^^258^2804^1^^^^1
 ;;^UTILITY(U,$J,358.3,56344,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56344,1,2,0)
 ;;=2^96372
 ;;^UTILITY(U,$J,358.3,56344,1,3,0)
 ;;=3^Administration of Inj, SC/IM
 ;;^UTILITY(U,$J,358.3,56345,0)
 ;;=96374^^258^2804^18^^^^1
 ;;^UTILITY(U,$J,358.3,56345,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56345,1,2,0)
 ;;=2^96374
 ;;^UTILITY(U,$J,358.3,56345,1,3,0)
 ;;=3^IV Push,Single Non-Chemo Drug
 ;;^UTILITY(U,$J,358.3,56346,0)
 ;;=51720^^258^2804^6^^^^1
 ;;^UTILITY(U,$J,358.3,56346,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56346,1,2,0)
 ;;=2^51720
 ;;^UTILITY(U,$J,358.3,56346,1,3,0)
 ;;=3^Bladder Instill Anticarc
 ;;^UTILITY(U,$J,358.3,56347,0)
 ;;=J0897^^258^2804^14^^^^1
 ;;^UTILITY(U,$J,358.3,56347,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56347,1,2,0)
 ;;=2^J0897
 ;;^UTILITY(U,$J,358.3,56347,1,3,0)
 ;;=3^Denosumab Inj 1 mg
 ;;^UTILITY(U,$J,358.3,56348,0)
 ;;=J1950^^258^2804^24^^^^1
 ;;^UTILITY(U,$J,358.3,56348,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56348,1,2,0)
 ;;=2^J1950
 ;;^UTILITY(U,$J,358.3,56348,1,3,0)
 ;;=3^Leuprolide Acetate Susp 3.75 mg
 ;;^UTILITY(U,$J,358.3,56349,0)
 ;;=J3489^^258^2804^34^^^^1
 ;;^UTILITY(U,$J,358.3,56349,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56349,1,2,0)
 ;;=2^J3489
 ;;^UTILITY(U,$J,358.3,56349,1,3,0)
 ;;=3^Zoledronic Acid 1 mg
 ;;^UTILITY(U,$J,358.3,56350,0)
 ;;=J3490^^258^2804^31^^^^1
 ;;^UTILITY(U,$J,358.3,56350,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,56350,1,2,0)
 ;;=2^J3490
 ;;^UTILITY(U,$J,358.3,56350,1,3,0)
 ;;=3^Unclassified Biologics
